ASC40 is an oral, selective small molecule inhibitor of FASN. Mechanisms of ASC40 for acne are (1) direct inhibition of facial sebum production, through in...
A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical signs and symptoms emerge and long before a...
Curasight to develop its proprietary uTRACE® PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for man...
Lupus Awareness Month occurs every May and is an opportunity for lupus-focused organizations to take intentional steps in creating awareness around lupus a...
There is growing recognition that the experimental model systems used in many cancer research projects, which include 2D cell cultures, patient-derived xen...
More than a million years ago, large chunks of the human genome were rearranged—a chance event during egg or sperm formation that led to the deletion...
The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angiopla...
"Our shared vision is one program offered at two sites to provide patients with the right care in a location close to home," said Dr. Glen Van Arsdell, who...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today...
A balanced microbiome plays an important role in maintaining human health by promoting protective immune responses and limiting excessive inflammation. But...
-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total revenue and the revenue from in...
CVL is the most comprehensive cardiovascular platform in the country. By partnering with CVL, FCCI will join a network of leading practices across the coun...
Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in...
© 2024 Biopharma Boardroom. All Rights Reserved.
